Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11+ or -A33+ allele-Reference-Cited by-同舟云学术

Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11+ or -A33+ allele

Published:2017-04 Issue:4 Volume:108 Page:598-603
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Sakamoto Shinjiro¹²³^ORCID,Matsueda Satoko²,Takamori Shinzo⁴,Toh Uhi⁴,Noguchi Masanori¹,Yutani Shigeru²^ORCID,Yamada Akira¹,Shichijo Shigeki²,Yamada Teppei⁵,Suekane Shigetaka⁶,Kawano Kouichiro⁷,Naitou Masayasu²,Sasada Tetsuro²⁸^ORCID,Hattori Noboru³,Kohno Nobuoki⁹,Itoh Kyogo²

Affiliation:

1. Research Center for Innovative Cancer Therapy; Kurume University; Kurume Japan

2. Cancer Vaccine Center; Kurume University; Kurume Japan

3. Department of Molecular and Internal Medicine School of Medicine; Graduate School of Biomedical and Health Sciences; Hiroshima University; Hiroshima Japan

4. Department of Surgery; Kurume University School of Medicine; Kurume Japan

5. Department of Gastroenterological Surgery; Fukuoka University School of Medicine; Fukuoka Japan

6. Department of Urology; Kurume University School of Medicine; Kurume Japan

7. Department of Obstetrics and Gynecology; Kurume University School of Medicine; Kurume Japan

8. Kanagawa Cancer Center Research Institute; Yokohama Japan

9. Hiroshima Cosmopolitan University; Hiroshima Japan

Funder

Japan Agency for Medical Research and Development

Regional Innovation Cluster Program of the Ministry of Education, Culture, Sports, Science and Technology of Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cas.13189/fullpdf

Reference18 articles.

1. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer;Noguchi;Prostate,2007

2. A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin;Matsumoto;BJU Int,2011

3. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer;Noguchi;Cancer Immunol Immunother,2010

4. An open-label, randomized phase ii trial of personalized peptide vaccination in patients with bladder cancer that progressed after platinum-based chemotherapy;Noguchi;Clin Cancer Res,2016

5. Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine;Noguchi;Cancer Immunol Immunother,2013

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Cancer Vaccine Research;ACS Biomaterials Science & Engineering;2023-11-03

2. Potential association factors for developing effective peptide-based cancer vaccines;Frontiers in Immunology;2022-07-27

3. Plasma level of prostate related‑antigen peptide‑reactive IgG is a prognostic factor of patients with breast cancer treated with personalized peptide vaccines;Experimental and Therapeutic Medicine;2021-06-25

4. Single-cell derived tumor organoids display diversity in HLA class I peptide presentation;Nature Communications;2020-10-21

5. HLA Polymorphisms Are Associated with Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia;Molecular Cancer Therapeutics;2020-10-20